MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II
H. Pannu(Institute of Molecular Medicine), Dianna M. Milewicz(The University of Texas Health Science Center), Chris Presley(Institute of Molecular Medicine), L. Maximilian Buja(The University of Texas Health Science Center at Houston), Steven E. Scherer(Howard Hughes Medical Institute), Christina L. Papke(Institute of Molecular Medicine), Van Tran‐Fadulu(Institute of Molecular Medicine), Anthony L. Estrera, Allan R. Brasier(The University of Texas Medical Branch at Galveston), C.S. Raman(University of Maryland, Baltimore), Yijun Liu(Guangdong Medical College), Hazim J. Safi(Methodist Hospital), D. Guo(Institute of Molecular Medicine), G. Wesley Vick(Baylor College of Medicine), Ali J. Marian(Czech Academy of Sciences, Institute of Biotechnology)
Cited by 289
Related Papers
Expert Consensus Document on the Treatment of Descending Thoracic Aortic Disease Using Endovascular Stent-Grafts
|The Annals of Thoracic Surgery|2008|855
Genetics of Thoracic and Abdominal Aortic Diseases
|Circulation Research|2019|441
The Society for Vascular Surgery Practice Guidelines: Management of the left subclavian artery with thoracic endovascular aortic repair
|Journal of Vascular Surgery|2009|425
The long QT syndrome in children. An international study of 287 patients.
|Circulation|1993|397
Characterization of the inflammatory and apoptotic cells in the aortas of patients with ascending thoracic aortic aneurysms and dissections
|Journal of Thoracic and Cardiovascular Surgery|2006|341